Algernon Pharmaceuticals

Algernon is a clinical-stage pharmaceutical company that is developing novel psychedelic molecules (based on DMT) for the treatment of stroke-related dysfunction.

Algernon Pharmaceuticals

Algernon Pharmaceuticals has raised a total of $8.9M in funding over 2 rounds. Their latest funding was raised on Mar 3, 2021 from a Post-IPO Equity round. Algernon raised $6.8 million in a Post-IPO Equity round on the 13th of May 2020.

“Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations, and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off-label prescription writing.“

Key Staff

• Christopher Moreau – CEO
• Christopher Bryan – VP Research & Operations
• Michael Sadhra – CFO & Director
• Ahmad Khalil – CMO

News

• Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke (press release, March 2021)